Company intelligence / Profile preview
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.
Shijiazhuang, Hebei, China
- Ownership
- Private
- Development stage
- Other
01
Overview
CSPC Zhongqi has multiple approved drugs including DPP-4 inhibitors (Jan 2025), IL-4Rα inhibitors (Sep 2024), PD-1 inhibitors (Jun 2024), and late-stage programs like Duvelisib hydrate (approved), Docetaxel albumin bound (Phase 3), and Enlonstobart (Phase 3).[6]
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugMonoclonal antibodyLiposomal DrugSynthetic peptideChemical drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd..